Fig 1: Mean (SD) plasma anti-FXa (A) and anti-FIIa (B) activity, and baseline-adjusted TFPI levels (C) versus time curves (semi-logarithmic scale) after fasting SC administration of single doses of the test or reference drug.Notes: Test drug is enoxaparin sodium 100 mg (10,000 IU anti-FXa/1.0 mL) manufactured by Rovi, Madrid, Spain (?). Reference drug is enoxaparin sodium 100 mg (Clexane® 10,000 IU anti-FXa/1.0 mL) manufactured by Sanofi, Maison Alfort, France (¦). Data shown from PK/PD analysis set (n=43).Abbreviations: PD, pharmacodynamic; PK, pharmacokinetic; SC, subcutaneous; TFPI, tissue factor pathway inhibitor.
Fig 2: Mean (SD) plasma anti-FXa (A) and anti-FIIa (B) activity, and baseline-adjusted TFPI levels (C) versus time curves (linear scale) after fasting of single doses of the test or reference drug.Notes: Test drug is enoxaparin sodium 100 mg (10,000 IU anti-FXa/1.0 mL) manufactured by Rovi, Madrid, Spain (?). Reference drug is enoxaparin sodium 100 mg (Clexane® 10,000 IU anti-FXa/1.0 mL) manufactured by Sanofi, Maison Alfort, France (¦). Data shown from PK/PD analysis set (n=43).Abbreviations: PD, pharmacodynamic; PK, pharmacokinetic; SC, subcutaneous; TFPI, tissue factor pathway inhibitor.
Supplier Page from Abcam for Human Tissue Factor Pathway Inhibitor ELISA Kit (TFPI)